Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections [1][2] - The company is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [2] Company Overview - Armata Pharmaceuticals utilizes proprietary bacteriophage-based technology for its therapeutic developments [2] - The company has in-house phage-specific cGMP manufacturing capabilities to support full commercialization of its products [2] Upcoming Events - Dr. Deborah Birx, the CEO of Armata, will present at the 7th Annual Bacteriophage Therapy Summit on March 13, 2025, in Boston, MA [1]

Core Insights - Armata Pharmaceuticals announced positive topline results from its Phase 2 "Tailwind" trial for AP-PA02, a novel inhaled multi-phage therapeutic targeting chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients [1][5] Study Design and Results - The Tailwind study was a multicenter, randomized, double-blind, placebo-controlled trial assessing the safety, pharmacokinetics, and efficacy of inhaled AP-PA02, conducted in two parallel cohorts [2] - Cohort A received AP-PA02 as monotherapy, while Cohort B received it in combination with inhaled antipseudomonal antibiotics, with dosing every 12 hours for 10 days and follow-up for approximately four weeks [2] - A post-hoc intent-to-treat analysis showed a statistically significant reduction in P.a. CFUs at day 17 (P=0.05) and day 24 (P=0.015) for AP-PA02 compared to placebo, indicating its effectiveness [3] - Approximately one-third of subjects treated with phage monotherapy exhibited at least a 2-log CFU reduction in P.a., while no reduction was observed in placebo subjects [3] Safety Profile - Safety data indicated that inhaled AP-PA02 was well-tolerated, with treatment-emergent adverse events being mild and self-limiting, although one serious adverse event was reported [4] Company Overview - Armata Pharmaceuticals is focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections, with a pipeline that includes candidates for Pseudomonas aeruginosa and Staphylococcus aureus [6]

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections [1][3] - The company is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [3] Company Overview - Armata Pharmaceuticals utilizes proprietary bacteriophage-based technology for drug development, which includes in-house phage specific cGMP manufacturing [3] - The CEO, Dr. Deborah Birx, is scheduled to present at the 5th Annual Phage Futures Annual Meeting on November 19, 2024, in Boston, MA [1]

Group 1 - Armata Pharmaceuticals reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.31 per share a year ago, resulting in an earnings surprise of 46.43% [1] - The company posted revenues of $2.97 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 230.33%, compared to revenues of $1.23 million in the same quarter last year [2] - Armata Pharmaceuticals has surpassed consensus revenue estimates two times over the last four quarters [2] Group 2 - The stock has underperformed, losing about 15.1% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.29 on revenues of $1.13 million, and for the current fiscal year, it is -$1.02 on revenues of $3 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 26% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]

Core Insights - Armata Pharmaceuticals reported financial results for Q3 2024, highlighting advancements in its bacteriophage therapeutic programs and financial performance improvements [1][2][3]. Clinical Developments - Enrollment for the Phase 2 "Tailwind" study of inhaled AP-PA02 in patients with non-cystic fibrosis bronchiectasis and chronic pulmonary Pseudomonas aeruginosa infection has been completed, with topline data expected by year-end [2][3]. - The company is preparing to initiate a pivotal bronchiectasis trial in 2025 for chronic pulmonary P. aeruginosa infection [2][3]. - Enrollment for the Phase 1b/2a "diSArm" study of intravenous AP-SA02 in patients with Staphylococcus aureus bacteremia has also been completed, with topline data anticipated in Q1 2025 [2][3]. - The company plans to meet with the U.S. FDA to align on the design of a pivotal Phase 3 bronchiectasis study for inhaled AP-PA02 [3]. Financial Performance - Grant revenue for Q3 2024 was $3.0 million, up from $1.2 million in Q3 2023, reflecting support for the AP-SA02 program [4]. - Research and development expenses increased to approximately $9.5 million in Q3 2024 from approximately $8.0 million in Q3 2023, indicating continued investment in clinical programs [5]. - General and administrative expenses decreased to approximately $3.2 million in Q3 2024 from approximately $3.6 million in Q3 2023, primarily due to reduced professional services costs [6]. - The loss from operations for Q3 2024 was approximately $9.8 million, an improvement from a loss of approximately $10.3 million in Q3 2023 [7]. - The net loss for Q3 2024 was $5.5 million, or $0.15 per share, compared to a net loss of $31.2 million, or $0.86 per share, in Q3 2023 [8]. Cash Position - As of September 30, 2024, the company held approximately $17.1 million in unrestricted cash and cash equivalents, an increase from $13.5 million as of December 31, 2023 [9].

Core Insights - Armata Pharmaceuticals has completed enrollment for its Phase 1b/2a diSArm study of intravenous AP-SA02, targeting Staphylococcus aureus bacteremia, with topline data expected in Q1 2025 [1][2] - The study aims to evaluate the safety and efficacy of AP-SA02 as a treatment option for patients suffering from serious bloodstream infections resistant to conventional antibiotics [2][3] Enrollment and Study Design - The diSArm study has enrolled 50 participants, marking a significant milestone in the development of AP-SA02 [1][2] - The study is designed as a randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of AP-SA02 in conjunction with best available antibiotic therapy [5] Clinical Safety and Efficacy - During the Phase 2a portion, Armata focused on the clinical safety of higher intravenous doses of AP-SA02, achieving dose escalation to 5E10 PFU every six hours without significant adverse events [2] - Two distinct subsets of subjects have shown evidence of phage persistence in the blood, indicating potential in vivo phage amplification [2] Future Plans and Regulatory Engagement - Armata plans to initiate a pivotal bacteremia efficacy study later in 2025, contingent on positive topline data [2][3] - The company intends to discuss the pivotal trial design with the U.S. Food and Drug Administration [3] Financial Support - The clinical development of AP-SA02 is partially funded by $21.6 million from the Defense Health Agency and Joint Warfighter Medical Research Program [4]

Core Insights - Armata Pharmaceuticals has published a paper detailing the structure of phage Pa193, a key candidate for its multi-phage anti-Pseudomonas clinical products [1][2] - The research enhances understanding of phage structure and function, potentially expanding clinical applications beyond Pseudomonas aeruginosa [3] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections [4] - The company is advancing a pipeline of natural and synthetic phage candidates targeting various pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus [4]

Core Viewpoint - Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements. Institutional investors utilize these estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. - The upgrade for Armata Pharmaceuticals suggests an improvement in its underlying business, which is expected to drive the stock price higher as investors respond to this trend [3]. Earnings Estimate Revisions - For the fiscal year ending December 2024, Armata Pharmaceuticals is projected to earn -$1.02 per share, reflecting a 46.6% change from the previous year's reported figure [5]. - Over the past three months, the Zacks Consensus Estimate for Armata Pharmaceuticals has increased by 46.5%, indicating a positive trend in earnings estimates [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [4]. - The upgrade of Armata Pharmaceuticals to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [7].

Core Insights - Armata Pharmaceuticals is focused on developing high-purity, pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections [1][6] - The company is presenting its phage development programs at the 2024 Military Health System Research Symposium, highlighting two candidates: inhaled AP-PA02 for Pseudomonas aeruginosa bronchiectasis and intravenous AP-SA02 for Staphylococcus aureus bacteremia [1][4] Clinical Development - The Phase 1b/2a diSArm study for intravenous AP-SA02 is 80% enrolled, with completion expected by the end of 2024 [2] - The clinical development of AP-SA02 is supported by a $21.6 million grant from the Department of Defense [2] - Preliminary data indicates that both intravenous AP-SA02 and inhaled AP-PA02 have been well tolerated, with promising pharmacokinetic results suggesting potential clinical benefits [4] Future Plans - The company aims to advance both AP-SA02 and AP-PA02 into pivotal Phase 3 trials in 2025, with the goal of introducing a new class of anti-infectives [3][4] - The poster presentation at MHSRS will discuss the ongoing clinical trials and their implications for treating difficult-to-treat infections [4][5] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, utilizing proprietary technology [6] - The company is developing a pipeline of natural and synthetic phage candidates targeting various pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus [6]

LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata's Corporate Controller, Richard Rychlik, will reta ...